GRIHealthcare · BiotechnologyThe 2 Wall Street analysts covering GRI Bio, Inc. hold a median 12-month price target of $21 — +1157.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores GRI Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (98): Smaller than most of the companies we track.
Value (5): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on GRI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +1157.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 June 2026 | Ascendiant Capital | Maintains | Buy | $40 → $32 |
| 1 June 2026 | Ascendiant Capital | Maintains | Buy | — |
| 11 Mar 2026 | Ascendiant Capital | Maintains | Buy | — |
| 8 Dec 2025 | Ascendiant Capital | Maintains | Buy | — |
| 22 Sept 2025 | Ascendiant Capital | Maintains | Buy | — |
| 11 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 May 2025 | Ascendiant Capital | Maintains | Buy | — |
| 21 Apr 2025 | Ascendiant Capital | Maintains | Buy | — |
| 14 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Dec 2024 | HC Wainwright & Co. | Initiates | Buy | — |
| 5 Dec 2024 | Ascendiant Capital | Maintains | Buy | — |
| 8 Oct 2024 | Ascendiant Capital | Initiates | Buy | $12 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GRI appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 74% of US stocks
Cheaper than 89% of US stocks
Cheaper than 58% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 8% of US stocks
Higher than 3% of US stocks
Higher than 98% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own GRI Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Bitcoin rose 4.6% to $72,475.25, a roughly 12% gain over two days, after trading near $63,000 earlier in the week. The move came as former President Trump voiced support for the Clarity Act and the Treasury increased buybacks.
Why it matters — The news does not reference GRI Bio, Inc., and the cryptocurrency market move has no evident direct bearing on the company.
The 2 Wall Street analysts covering GRI Bio, Inc. have a median 12-month price target of $21, with estimates ranging from $10 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering GRI Bio, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks GRI Bio, Inc. 30 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, GRI Bio, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +1157.5% from the last close, and Ticker Nerd's factor model ranks GRI Bio, Inc. 30 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering GRI Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GRI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $32 over the next 12 months.
GRI Bio, Inc. returned -95.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Gri Bio Inc. is a biotechnology company dedicated to the development of innovative therapies, particularly focusing on immunology and inflammatory diseases.
The most recent item we track (New York Post, 20 Aug 2026): "Bitcoin surges above $70K as Trump backs Clarity Act, Treasury ramps up buybacks". Bitcoin rose 4.6% to $72,475.25, a roughly 12% gain over two days, after trading near $63,000 earlier in the week. The move came as former President Trump voiced support for the Clarity Act and the Treasury increased buybacks.
Gri Bio Inc. is a biotechnology company dedicated to the development of innovative therapies, particularly focusing on immunology and inflammatory diseases. The primary function of the company is to research and create novel treatments that address unmet medical needs, leveraging cutting-edge scientific discoveries to advance human health. Their work predominantly impacts the healthcare and pharmaceutical sectors, with a significant emphasis on improving patient outcomes in challenging disease areas. Gri Bio Inc. plays a crucial role in the biotechnology market, contributing to the expansive growth and diversification of therapeutic options available to clinicians. By prioritizing transparency, collaboration, and rigorous scientific evaluation, the company aims to foster substantial progress within the biotech field, offering valuable advancements in medicine to stakeholders, including patients, healthcare providers, and the broader scientific community. Gri Bio Inc.'s commitment to excellence and pioneering research propels its significance and potential influence in the financial markets by addressing critical health challenges through breakthrough therapies.
CEO Dr. W. Marc Hertz Ph.D. · 3 employees · United States · https://www.gribio.com